Focal therapy for prostate cancer: Rationale and treatment opportunities

Clinical Oncology

Volumn 25, Issue 8, 2013, Pages 461-473

  Kasivisvanathan, V ^a,b   Emberton, M ^a,b   Ahmed, H U ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Focal ablation; Focal therapy; Future perspective; Outcomes; Prostate cancer; Rationale

Indexed keywords

AMINOLEVULINIC ACID; HEMATOPORPHYRIN; PADELIPORFIN; PHOTOFRIN; TEMOPORFIN;

ARTICLE; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER THERAPY; CRYOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FOCAL THERAPY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER;

FOCAL ABLATION; FOCAL THERAPY; FUTURE PERSPECTIVE; OUTCOMES; PROSTATE CANCER; RATIONALE;

HUMANS; MALE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84880631898     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.05.002     Document Type: Article

References (108)

1. Wilt T.J., MacDonald R., Rutks I., Shamliyan T.A., Taylor B.C., Kane R.L. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008, 148(6):435-448.
2. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. NEngl J Med 2008, 358(12):1250-1261.
3. Boorjian S.A., Eastham J.A., Graefen M., et al. Acritical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 2012, 61(4):664-675.
4. Resnick M.J., Koyama T., Fan K.H., et al. Long-term functional outcomes after treatment for localized prostate cancer. NEngl J Med 2013, 368(5):436-445.
5. Wei J.T., Dunn R.L., Sandler H.M., et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. JClin Oncol 2002, 20(2):557-566.
6. Welch H.G., Albertsen P.C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. JNatl Cancer Inst 2009, 101(19):1325-1329.
7. Cooperberg M.R., Lubeck D.P., Meng M.V., Mehta S.S., Carroll P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. JClin Oncol 2004, 22(11):2141-2149.
8. Collin S.M., Martin R.M., Metcalfe C., et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008, 9(5):445-452.
9. Schroder F.H., Hugosson J., Roobol M.J., et al. Prostate-cancer mortality at 11 years of follow-up. NEngl J Med 2012, 366(11):981-990.
10. Andriole G.L., Crawford E.D., Grubb R.L., et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. JNatl Cancer Inst 2012, 104(2):125-132.
11. Roobol M.J., Kerkhof M., Schroder F.H., et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009, 56(4):584-591.
12. Nordstrom T., Aly M., Clements M.S., Weibull C.E., Adolfsson J., Gronberg H. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol 2013 Mar, 63(3):419-425.
13. Wilt T.J., Brawer M.K., Jones K.M., et al. Radical prostatectomy versus observation for localized prostate cancer. NEngl J Med 2012, 367(3):203-213.
14. Dall'era M.A., Albertsen P.C., Bangma C., et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012, 62(6):976-983.
15. Godtman R.A., Holmberg E., Khatami A., Stranne J., Hugosson J. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial. Eur Urol 2013, 63(1):101-107.
16. Litwin M.S., Lubeck D.P., Spitalny G.M., Henning J.M., Carroll P.R. Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer 2002, 95(1):54-60.
17. Galbraith M.E., Ramirez J.M., Pedro L.W. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol Nursing Forum 2001, 28(3):551-560.
18. Wallace M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nursing Forum 2003, 30(2):303-309.
19. Dale W., Bilir P., Han M., Meltzer D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer 2005, 104(3):467-478.
20. McVey G.P., McPhail S., Fowler S., McIntosh G., Gillatt D., Parker C.C. Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int 2010, 106(8):1161-1164.
21. Ahmed H.U., Pendse D., Illing R., Allen C., van der Meulen J.H., Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer?. Nat Clin Pract Oncol 2007, 4(11):632-642.
22. Eggener S.E., Scardino P.T., Carroll P.R., et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. JUrol 2007, 178(6):2260-2267.
23. Lindner U., Trachtenberg J., Lawrentschuk N. Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol 2010, 7(10):562-571.
24. Ahmed H.U., Hindley R.G., Dickinson L., et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012, 13(6):622-632.
25. Barret E., Ahallal Y., Sanchez-Salas R., et al. Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 2013 Apr, 63(4):618-622.
26. Mouraviev V., Villers A., Bostwick D.G., Wheeler T.M., Montironi R., Polascik T.J. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int 2011, 108(7):1074-1085.
27. Villers A., McNeal J.E., Freiha F.S., Stamey T.A. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992, 70(9):2313-2318.
28. Wise A.M., Stamey T.A., McNeal J.E., Clayton J.L. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002, 60(2):264-269.
29. Noguchi M., Stamey T.A., McNeal J.E., Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. JUrol 2003, 170(2 Pt 1):459-463.
30. Liu W., Laitinen S., Khan S., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009, 15(5):559-565.
31. Guo C.C., Wang Y., Xiao L., Troncoso P., Czerniak B.A. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. Hum Pathol 2012, 43(5):644-649.
32. Stamey T.A., Freiha F.S., McNeal J.E., Redwine E.A., Whittemore A.S., Schmid H.P. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993, 71(3 Suppl.):933-938.
33. Epstein J.I., Walsh P.C., Carmichael M., Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994, 271(5):368-374.
34. Ward J.F., Nakanishi H., Pisters L., Babaian R.J., Troncoso P. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int 2009, 104(4):490-497.
35. Muto S., Yoshii T., Saito K., Kamiyama Y., Ide H., Horie S. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 2008, 38(3):192-199.
36. Karavitakis M., Winkler M., Abel P., Livni N., Beckley I., Ahmed H.U. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 2011, 14(1):46-52.
37. Bott S.R., Ahmed H.U., Hindley R.G., Abdul-Rahman A., Freeman A., Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int 2010, 106(11):1607-1611.
38. van As N.J., Norman A.R., Thomas K., et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008, 54(6):1297-1305.
39. Ahmed H.U., Emberton M. Re: Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. JUrol 2008, 180(2):780-781. author reply 1-3.
40. Bahn D., de Castro Abreu A.L., Gill I.S., et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012, 62(1):55-63.
41. Ahmed H.U., Emberton M. Focal HIFU for prostate cancer-authors' reply. Lancet Oncol 2012, 13(7):e284.
42. D'Amico A.V., Cote K., Loffredo M., Renshaw A.A., Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. JClin Oncol 2002, 20(23):4567-4573.
43. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280(11):969-974.
44. Stolzenburg J.U., Bynens B., Do M., Rabenalt R., Katsakiori P.F., Liatsikos E. Salvage laparoscopic extraperitoneal radical prostatectomy after failed high-intensity focused ultrasound and radiotherapy for localized prostate cancer. Urology 2007, 70(5):956-960.
45. Ahmed H.U., Cathcart P., McCartan N., et al. Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study. Cancer 2012, 118(17):4148-4155.
46. Eisenberg M.L., Shinohara K. Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. Urology 2008, 72(6):1315-1318.
47. Pucar D., Shukla-Dave A., Hricak H., et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005, 236(2):545-553.
48. Cellini N., Morganti A.G., Mattiucci G.C., et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002, 53(3):595-599.
49. Arrayeh E., Westphalen A.C., Kurhanewicz J., et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 2012, 82(5):e787-793.
50. Heidenreich A, Bastian PJ, Bellmunt J, etal. European Association of Urology 2012 guidelines on prostate cancer. Available at:. http://www.uroweb.org/guidelines/online-guidelines/.
51. Crawford E.D., Rove K.O., Barqawi A.B., et al. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate 2013 May, 73(7):778-787.
52. Hu Y., Ahmed H.U., Carter T., et al. Abiopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU Int 2012, 110(6):812-820.
53. Onik G., Miessau M., Bostwick D.G. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. JClin Oncol 2009, 27(26):4321-4326.
54. Moran B.J., Braccioforte M.H. Stereotactic transperineal prostate biopsy. Urology 2009, 73(2):386-388.
55. Demura T., Hioka T., Furuno T., et al. Differences in tumor core distribution between palpable and nonpalpable prostate tumors in patients diagnosed using extensive transperineal ultrasound-guided template prostate biopsy. Cancer 2005, 103(9):1826-1832.
56. Pinkstaff D.M., Igel T.C., Petrou S.P., Broderick G.A., Wehle M.J., Young P.R. Systematic transperineal ultrasound-guided template biopsy of the prostate: three-year experience. Urology 2005, 65(4):735-739.
57. Kasivisvanathan V., Dufour R., Moore C.M., et al. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. JUrol 2013, 189(3):860-866.
58. Pallwein L., Mitterberger M., Gradl J., et al. Value of contrast-enhanced ultrasound and elastography in imaging of prostate cancer. Curr Opin Urol 2007, 17(1):39-47.
59. Salomon G., Kollerman J., Thederan I., et al. Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur Urol 2008, 54(6):1354-1362.
60. Taverna G., Morandi G., Seveso M., et al. Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in transrectal systematic prostate biopsy sampling. BJU Int 2011, 108(11):1723-1727.
61. Simmons L.A., Autier P., Zat'ura F., et al. Detection, localisation and characterisation of prostate cancer by prostate HistoScanning. BJU Int 2012 Jul, 110(1):28-35.
62. Taverna G., Magnoni P., Giusti G., et al. Impact of real-time elastography versus systematic prostate biopsy method on cancer detection rate in men with a serum prostate-specific antigen between 2.5 and 10ng/ml. ISRN Oncology 2012, 2013:584-672.
63. Puech P., Potiron E., Lemaitre L., et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009, 74(5):1094-1099.
64. Villers A., Puech P., Mouton D., Leroy X., Ballereau C., Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. JUrol 2006, 176(6 Pt 1):2432-2437.
65. Woodfield C.A., Tung G.A., Grand D.J., Pezzullo J.A., Machan J.T., Renzulli J.F. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 2010, 194(4):W316-W322.
66. Verma S., Rajesh A., Morales H., et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 2011, 196(2):374-381.
67. Zakian K.L., Sircar K., Hricak H., et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005, 234(3):804-814.
68. Barentsz J.O., Richenberg J., Clements R., et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012, 22(4):746-757.
69. Dickinson L., Ahmed H.U., Allen C., et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011, 59(4):477-494.
70. Portalez D., Mozer P., Cornud F., et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 2012, 62(6):986-996.
71. Bomers J.G., Sedelaar J.P., Barentsz J.O., Futterer J.J. MRI-guided interventions for the treatment of prostate cancer. AJR Am J Roentgenol 2012, 199(4):714-720.
72. Cepek J., Chronik B., Lindner U., Trachtenberg J., Fenster A. Development of an MRI-compatible device for prostate focal therapy. Med Image Comput Comput Assist Interv 2012, 15(Pt 1):455-462.
73. Lindner U., Ghai S., Spensieri P., et al. Focal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience. Can Urol Assoc J 2012, 6(6):E283-E286.
74. Ahmed H.U., Freeman A., Kirkham A., et al. Focal therapy for localized prostate cancer: a phase I/II trial. JUrol 2011, 185(4):1246-1254.
75. El Fegoun A.B., Barret E., Prapotnich D., et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol 2011, 37(2):213-219. discussion 20-22.
76. Bahn D.K., Silverman P., Lee F., Badalament R., Bahn E.D., Rewcastle J.C. Focal prostate cryoablation: initial results show cancer control and potency preservation. JEndourol 2006, 20(9):688-692.
77. Lambert E.H., Bolte K., Masson P., Katz A.E. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 2007, 69(6):1117-1120.
78. Ellis D.S., Manny T.B., Rewcastle J.C. Cryoablation as primary treatment for localized prostate cancer followed by penile rehabilitation. Urology 2007, 69(2):306-310.
79. Onik G., Vaughan D., Lotenfoe R., Dineen M., Brady J. The "male lumpectomy": focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 2008, 26(5):500-505.
80. Windahl T., Andersson S.O., Lofgren L. Photodynamic therapy of localised prostatic cancer. Lancet 1990, 336(8723):1139.
81. Zaak D., Sroka R., Hoppner M., et al. Photodynamic therapy by means of 5-ALA induced PPIX in human prostate cancer-preliminary results. Med Laser Appl 2003, 18:91-95.
82. Moore C.M., Nathan T.R., Lees W.R., et al. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Lasers Surg Med 2006, 38(5):356-363.
83. Amin Z., Lees W.R., Bown S.G. Technical note: interstitial laser photocoagulation for the treatment of prostatic cancer. Br J Radiol 1993, 66(791):1044-1047.
84. Lindner U., Weersink R.A., Haider M.A., et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. JUrol 2009, 182(4):1371-1377.
85. Lindner U., Lawrentschuk N., Weersink R.A., et al. Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur Urol 2010, 57(6):1111-1114.
86. Raz O., Haider M.A., Davidson S.R., et al. Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur Urol 2010, 58(1):173-177.
87. Lindner U., Louis S.A., Colquhoun J.A., et al. First robotic magnetic resonance-guided laser focal therapy for prostate cancer: a case report and review of the literature. Interven Oncol Soc J 2011, 1(1):69-77.
88. D'Amico A.V., Tempany C.M., Schultz D., et al. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology 2003, 62(6):1063-1067.
89. Albert M., Tempany C.M., Schultz D., et al. Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer 2003, 98(5):949-954.
90. Hsu C.C., Hsu H., Pickett B., et al. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys 2013, 85(2):370-377.
91. McKenna D.A., Coakley F.V., Westphalen A.C., et al. Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy - initial experience. Radiology 2008, 247(1):141-146.
92. Langley S., Ahmed H.U., Al-Qaisieh B., et al. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int 2012, 109(Suppl. 1):7-16.
93. Ares C., Popowski Y., Pampallona S., et al. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study. Int J Radiat Oncol Biol Phys 2009, 75(3):656-663.
94. Fuller D.B., Naitoh J., Lee C., Hardy S., Jin H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 2008, 70(5):1588-1597.
95. King C.R., Brooks J.D., Gill H., Pawlicki T., Cotrutz C., Presti J.C. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009, 73(4):1043-1048.
96. Shariat S.F., Raptidis G., Masatoschi M., Bergamaschi F., Slawin K.M. Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate 2005, 65(3):260-267.
97. Djavan B., Zlotta A.R., Susani M., et al. Transperineal radiofrequency interstitial tumor ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination. Urology 1997, 50(6):986-992. discussion 92-93.
98. Thomson K.R., Cheung W., Ellis S.J., et al. Investigation of the safety of irreversible electroporation in humans. JVasc Interv Radiol 2011, 22(5):611-621.
99. Kasivisvanathan V., Thapar A., Oskrochi Y., Picard J., Leen E.L. Irreversible electroporation for focal ablation at the porta hepatis. Cardiovasc Intervent Radiol 2012, 35(6):1531-1534.
100. Krishnan S., Diagaradjane P., Cho S.H. Nanoparticle-mediated thermal therapy: evolving strategies for prostate cancer therapy. Int J Hyperthermia 2010, 26(8):775-789.
101. Rouviere O., Glas L., Girouin N., et al. Prostate cancer ablation with transrectal high-intensity focused ultrasound: assessment of tissue destruction with contrast-enhanced US. Radiology 2011, 259(2):583-591.
102. Rouviere O., Lyonnet D., Raudrant A., et al. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001, 40(3):265-274.
103. Rouviere O., Girouin N., Glas L., et al. Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol 2010, 20(1):48-55.
104. Rouviere O., Vitry T., Lyonnet D. Imaging of prostate cancer local recurrences: why and how?. Eur Radiol 2010, 20(5):1254-1266.
105. Kirkham A.P., Emberton M., Hoh I.M., Illing R.O., Freeman A.A., Allen C. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology 2008, 246(3):833-844.
106. Ellis D.S., Manny T.B., Rewcastle J.C. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology 2007, 70(6 Suppl.):9-15.
107. Gburek B.M., Kollmorgen T.A., Qian J., D'Souza-Gburek S.M., Lieber M.M., Jenkins R.B. Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization. JUrol 1997, 157(1):223-227.
108. Relton C., Torgerson D., O'Cathain A., Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design. Br Med J 2010, 340:c1066.